
Strive buys US$94.5M in bitcoin as SATA preferred shares rise
CEO Matt Cole says SATA supplied 85 per cent of capital raised; cash stood at US$248.8 million on Sept. 25.

First U.S. approval covers peripheral thyrotoxicosis in MCT8 deficiency; Egetis expects commercial availability eight to 10 weeks after Sept. 28.

CEO Matt Cole says SATA supplied 85 per cent of capital raised; cash stood at US$248.8 million on Sept. 25.

The Llama infill result comes as mobile crushing helps keep the Nunavut mine on course for 170,000 to 200,000 ounces in 2026.
A strategic investor exercised a participation right as the company's two September financings issued 13.1 million new shares.
A signed trial pact covers ivonescimab and sonesitatug vedotin in gastrointestinal cancers; Summit expects the share sale to close by Oct. 2.

The Sept. 29 announcement assigns the other US$500M to five Samsung affiliates but does not break down their commitments or name a Helix project.

The cannabis banking platform expects SHFS to keep its Nasdaq ticker and round fractional holdings up when split-adjusted trading begins Sept. 30.

The three-year ceiling includes options; DLH did not disclose the funded base period or update its US$408.5M June 30 backlog.

The Sept. 25 adult Parkinson's approval clears one condition for a payment-rights purchase expected to close Sept. 29.
The closed SPR2015 deal carries a US$400M upfront payment; further value depends on development and commercial milestones.
The perpetual, royalty-free agreement covers two brands, while a Texas launch still requires final state licensure and regulatory approval.
Blöte starts Oct. 1 as Canopy seeks German medical cannabis growth; its June quarter international cannabis revenue was C$9.6M.
The Sept. 25 charter amendment doubles common-share capacity and raises the cannabis landlord’s preferred-share ceiling without a shareholder vote.
The Sept. 28 vote approved articles changes, preferred allotments and market repurchases; a possible IPO still needs an FCA-approved prospectus.
The four-year line starts at SOFR plus 175 basis points and can back utility and equipment obligations with letters of credit.
Most of the award remains unfunded as Amprius targets 12 million cells a year from a converted U.S. line by early 2028.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
Smackover Lithium can send optional tonnes to another buyer while it seeks about US$1.1 billion of debt and an investment decision in 2026.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
Its Texas subsidiary would pay PsyLabs the milestones for the first drug candidate; the binding terms lapse without a definitive agreement by Nov. 30.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The 18-month HHS award covers all three Xacta modules plus integration, training and migration services.
Hanwa and JOGMEC would take 15% at closing, while NextSource targets a second-half 2027 ramp-up for the plant's first phase.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
The first Cape Station block is due for contractual commercial operation by Oct. 1, while two more blocks target Jan. 1, 2027.

The term starts when Building One is ready for service; Fermi gave no date or contract value in its Sept. 24 announcement.

OPG's Sept. 25 supplier post names ATS's tooling and a 125,000-square-foot facility addition without stating a contract value or delivery date.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The Sept. 25 meeting lacked quorum, leaving shareholders until 9 a.m. EDT on Oct. 23 to submit proxies before the reconvened vote.

Holders will weigh a new parent company, a Delaware move and a voting-share sunset extension as Cresco pursues a potential U.S. listing.

The applications pair LSD, ketamine and ibogaine with N-acylethanolamines, while the scope of any patent rights remains undecided.

Curaleaf urged a signature on Sept. 23; A10698B would let regulators seek suspensions and impose daily civil penalties.